CUMBERLAND PHARMACEUTICALS (CPIX) Stock Analyst Earnings Estimates
NASDAQ:CPIX - Nasdaq - US2307701092 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | ||
|---|---|---|---|---|
| Revenue YoY % growth | 35.985M -3.89% | 42.011M 16.75% | 39.553M -5.85% | |
| EBITDA YoY % growth | -1.671M -16.86% | 123.18K 107.37% | -1.275M -1,134.97% | |
| EBIT YoY % growth | -6.277M -1.58% | -5.205M 17.08% | -6.211M -19.33% | |
| Operating Margin | -17.44% | -12.39% | -15.70% | |
| EPS YoY % growth | N/A | N/A | 0.18 |
All data in USD
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.02 -200.00% | % | ||
| Q2 2024 Q2Q % growth | 0.01 -93.75% | % | ||
| Q1 2024 Q2Q % growth | -0.05 -145.45% | % | ||
| Q4 2023 Q2Q % growth | -0.11 -120.00% | % | ||
| Q3 2023 Q2Q % growth | 0.02 -80.00% | % | ||
| Q3 2022 Q2Q % growth | 0.10 600.00% | % | ||
| Q3 2021 Q2Q % growth | -0.02 -200.00% | % | ||
| Q2 2021 Q2Q % growth | 0.00 -100.00% | -0.07 | 0.07 | 100.00% |
| Q1 2021 Q2Q % growth | 0.07 600.00% | -0.07 | 0.14 | 198.04% |
| Q4 2020 Q2Q % growth | 0.01 -88.89% | -0.01 | 0.02 | 198.04% |
| Q3 2020 Q2Q % growth | 0.02 100.00% | -0.07 | 0.09 | 128.01% |
| Q2 2020 Q2Q % growth | 0.08 -20.00% | 0.03 | 0.05 | 161.44% |
| Q1 2020 Q2Q % growth | 0.01 -90.91% | 0.02 | -0.01 | -50.98% |
| Q4 2019 Q2Q % growth | 0.09 | 0.01 | 0.08 | 782.35% |
| Q3 2019 Q2Q % growth | 0.01 | 0.11 | -0.10 | -91.09% |
| Q2 2019 Q2Q % growth | 0.10 | 0.07 | 0.03 | 40.06% |
| Q1 2019 Q2Q % growth | 0.11 | -0.11 | 0.22 | 198.04% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 9.09M -9.91% | % | ||
| Q2 2024 Q2Q % growth | 9.85M -9.55% | % | ||
| Q1 2024 Q2Q % growth | 8.5M -7.91% | % | ||
| Q4 2023 Q2Q % growth | 9.35M 2.48% | % | ||
| Q3 2023 Q2Q % growth | 10.09M -11.59% | % | ||
| Q2 2023 Q2Q % growth | 10.89M 5.74% | % | ||
| Q1 2023 Q2Q % growth | 9.23M -17.41% | % | ||
| Q4 2022 Q2Q % growth | 9.124M 9.66% | % | ||
| Q3 2022 Q2Q % growth | 11.413M 41.38% | % | ||
| Q2 2022 Q2Q % growth | 10.299M 13.73% | % | ||
| Q1 2022 Q2Q % growth | 11.175M 6.03% | % | ||
| Q4 2021 Q2Q % growth | 8.32M -18.91% | % | ||
| Q3 2021 Q2Q % growth | 8.073M -12.73% | % | ||
| Q2 2021 Q2Q % growth | 9.055M -5.67% | 8.742M | 313.48K | 3.59% |
| Q1 2021 Q2Q % growth | 10.54M 26.53% | 8.673M | 1.867M | 21.53% |
| Q4 2020 Q2Q % growth | 10.26M 10.20% | 9.978M | 282K | 2.83% |
| Q3 2020 Q2Q % growth | 9.25M 33.29% | 8.786M | 464K | 5.28% |
| Q2 2020 Q2Q % growth | 9.6M 1.91% | 9.452M | 148K | 1.57% |
| Q1 2020 Q2Q % growth | 8.33M -4.58% | 9.649M | -1.319M | -13.67% |
| Q4 2019 Q2Q % growth | 9.31M | 11.569M | -2.259M | -19.53% |
| Q3 2019 Q2Q % growth | 6.94M | 12.906M | -5.966M | -46.23% |
| Q2 2019 Q2Q % growth | 9.42M | 12.838M | -3.418M | -26.62% |
| Q1 2019 Q2Q % growth | 8.73M | 10.914M | -2.184M | -20.01% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A |
| Revenue | N/A | N/A | N/A | N/A |